163 related articles for article (PubMed ID: 608570)
21. Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones.
Iwamura K
Tokai J Exp Clin Med; 1982 Nov; 7(6):671-83. PubMed ID: 7184199
[TBL] [Abstract][Full Text] [Related]
22. Nucleation time of gall bladder bile in gall stone patients: influence of bile acid treatment.
Sahlin S; Ahlberg J; Angelin B; Reihnér E; Einarsson K
Gut; 1991 Dec; 32(12):1554-7. PubMed ID: 1773966
[TBL] [Abstract][Full Text] [Related]
23. Analysis of response to ursodeoxycholic acid for gallstone dissolution.
Bateson MC; Hill A; Bouchier IA
Digestion; 1980; 20(5):358-64. PubMed ID: 7390061
[TBL] [Abstract][Full Text] [Related]
24. [Oral dissolving treatment of gallbladder calculi: focus in 1989].
Erlinger S
Ann Chir; 1989; 43(6):417-9. PubMed ID: 2817740
[TBL] [Abstract][Full Text] [Related]
25. Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
Maton PN; Murphy GM; Dowling RH
Gut; 1980 Dec; 21(12):1082-6. PubMed ID: 7461467
[TBL] [Abstract][Full Text] [Related]
26. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.
Iser JH; Sali A
Drugs; 1981 Feb; 21(2):90-119. PubMed ID: 7009140
[TBL] [Abstract][Full Text] [Related]
27. Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.
Iser JH; Maton PN; Murphy GM; Dowling RH
Br Med J; 1978 Jun; 1(6126):1509-12. PubMed ID: 656777
[TBL] [Abstract][Full Text] [Related]
28. Best-buy regimen of ursodeoxycholic acid for patients with gallstones.
Lanzini A; Facchinetti D; Pigozzi MG; Bettini L; Muiesan G
Scand J Gastroenterol; 1991 May; 26(5):551-6. PubMed ID: 1871547
[TBL] [Abstract][Full Text] [Related]
29. Faecal bile acid loss and bile acid pool size during short-term treatment with ursodeoxycholic and chenodeoxycholic acid in patients with radiolucent gallstones.
Salvioli G; Salati R
Gut; 1979 Aug; 20(8):698-704. PubMed ID: 488763
[TBL] [Abstract][Full Text] [Related]
30. Final outcome of ursodeoxycholic acid treatment in 126 patients with radiolucent gallstones.
Gleeson D; Ruppin DC; Saunders A; Murphy GM; Dowling RH
Q J Med; 1990 Jul; 76(279):711-29. PubMed ID: 2217675
[TBL] [Abstract][Full Text] [Related]
31. Medical dissolution of gallstones by ursodeoxycholic acid: a clinical trial on 14 patients.
Lin JT; Wang JT; Wang TH; Su CT
Taiwan Yi Xue Hui Za Zhi; 1989 Apr; 88(4):370-6. PubMed ID: 2794937
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic acid for adjuvant therapy with extracorporeal shock wave lithotripsy of gallstones.
Fromm H
J Clin Gastroenterol; 1988; 10 Suppl 2():S18-21. PubMed ID: 3062080
[TBL] [Abstract][Full Text] [Related]
33. The effect of diet on bile acid kinetics and biliary lipid secretion in gallstone patients treated with ursodeoxycholic acid.
Frenkiel PG; Lee DW; Cohen H; Gilmore CJ; Resser K; Bonorris GG; Marks JW; Schoenfield LJ
Am J Clin Nutr; 1986 Feb; 43(2):239-50. PubMed ID: 3004189
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy.
Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
Drugs; 1984 Feb; 27(2):95-131. PubMed ID: 6365507
[TBL] [Abstract][Full Text] [Related]
35. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group.
Petroni ML; Jazrawi RP; Pazzi P; Lanzini A; Zuin M; Pigozzi MG; Fracchia M; Galatola G; Alvisi V; Heaton KW; Podda M; Northfield TC
Aliment Pharmacol Ther; 2001 Jan; 15(1):123-8. PubMed ID: 11136285
[TBL] [Abstract][Full Text] [Related]
36. Radiolucent gallstone dissolution with bedtime UDCA administration.
Conte D; Bozzani A; Sironi L; Rocca F; Camassa L; Bianchi PA
Digestion; 1981; 22(6):302-4. PubMed ID: 7333417
[TBL] [Abstract][Full Text] [Related]
37. Ursodeoxycholic acid for the dissolution of radiolucent gall bladder stones.
Neligan P; Bateson MC; Trash DB; Ross PE; Bouchier IA
Digestion; 1983; 28(4):225-33. PubMed ID: 6671484
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with ursodeoxycholic acid alone.
Podda M; Zuin M; Battezzati PM; Ghezzi C; de Fazio C; Dioguardi ML
Gastroenterology; 1989 Jan; 96(1):222-9. PubMed ID: 2642440
[TBL] [Abstract][Full Text] [Related]
39. Increase in serum total cholesterol and low-density lipoprotein cholesterol by high-dose chenodeoxycholic acid in patients with radiolucent gallstones significantly reversed during preventive low dose after gallstone dissolution.
Pérez-Aguilar F; Bretó M; Alegre B; Berenguer J
Digestion; 1985; 31(4):225-33. PubMed ID: 4007294
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
